• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Daily Dose: Over-the-Counter Naloxone

Article

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.


On November 17, 2022, we reported on a preliminary assessment from the US Food and Drug Administration (FDA) that showed certain naloxone products may be approvable for nonprescription use.

The assessment

The FDA's Federal Register notice included a preliminary assessment that naloxone nasal spray (up to 4 mg) and naloxone autoinjector for intramuscular or subcutaneous use (up to 2 mg) may be approvable as safe and effective for nonprescription use for the prevention of overdose deaths.

"We need additional data such as product-specific data on the nonprescription user interface design, including packaging and labeling, to make a conclusive determination in this respect," wrote the FDA.

Click here for more details.


Related Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Related Content
© 2024 MJH Life Sciences

All rights reserved.